Again, relatively low sensitivities and performances were observed for the individual DMMs in cfDNA between early-stage HCC patients with small tumor sizes and those with cirrhosis, and the combination of ASAP/GAAD with the 5 DMMs or with FOXD3 achieved an AUC of 0.807 and 0.807 versus 0.785 for ASAP/GAAD alone (Fig. 5D). This evidence concerns the gene FOXD3 and hepatocellular carcinoma.